Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
Oncurie
company
About
Oncurie focuses on creating the technology to deliver radionuclides selectively to metastatic tissue to treat metastatic cancer.
Details
- Last Funding Type
- Grant
- Last Funding Money Raised
- $255.73K
- Industries
- Biotechnology,Chemical Engineering,Health Care,Therapeutics
- Founded date
- Jan 1, 2021
- Operating Status
- Active
Oncurie develops targeted radionuclide therapy to create a cure for metastatic cancer through the use of novel molecular radionuclide technology, enabling healthcare providers to cure their patients. They are creating the technology to deliver radionuclides selectively to metastatic tissues.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$255.73K
Oncurie has raised a total of
$255.73K
in funding over 2 rounds. Their latest funding was raised on
Jan 21, 2022 from a Grant round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jan 21, 2022 | Grant | $255.73K | 1 |
National Science Foundation
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
1
Oncurie is funded by 1 investors.
National Science Foundation
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
National Science Foundation
|
Yes | Grant |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
